Like all wellness and peptide therapies, side effects may occur in some patients
Common requirements include documented BMI meeting the threshold, proof of previous weight loss attempts (usually 3-6 months of supervised diet and exercise), at least one qualifying comorbidity, and sometimes evidence that other treatments have been tried and failed
Mutations in these genes not only cause severe obesity but also frequently lead to a broad spectrum of neurological phenotypes, including intellectual disability, developmental delay, and behavioral abnormalities (e.g., autism-like features), highlighting the foundational role of hypothalamic development in energy homeostasis [12,14]
While injectable GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment landscape for obesity and type 2 diabetes, their reliance on subcutaneous injection remains a significant barrier to broader adoption
